Form 4: VolitionRx Executive Amends Stock Options

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, amended her stock options, effectively replacing older options with new ones.

Summary

• Ann-Louise Batchelor, the Group Chief Marketing Officer of VolitionRx Ltd, has amended her stock options.
• The amendment involved the cancellation of existing options and the grant of replacement options.
• The original options were granted on February 11, 2019, vested after 12 months, and were exercisable for five years.
• The replacement options are fully vested and expire on February 11, 2029, which is ten years from the original grant date.
• Both the old and new options have an exercise price of $3.25.
• The transaction involved 40,000 options.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option amendments, which is neither positive nor negative in itself.

Positives

• The new options have a longer expiry date, extending the potential benefit for the executive.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when executives make changes to their stock holdings or options. It is a routine disclosure and does not indicate any unusual activity.

Comparison to Industry Standards

• Stock option grants and amendments are a common practice for executive compensation in publicly traded companies.
• The vesting and expiry terms of the options are within typical ranges for such grants.
• The exercise price of $3.25 is specific to VolitionRx and would need to be compared to the company's share price and other compensation packages to assess its relative value.

Stakeholder Impact

• The amendment of stock options may have a minor impact on shareholders by potentially increasing the number of shares available in the future.

Key Dates

Keywords

stock options, executive compensation, insider trading, form 4, VNRX, VolitionRx, options amendment